Literature DB >> 4812958

The chemotherapy of intracerebral vs subcutaneous murine gliomas. A comparative study of the effect of VM 26.

W R Shapiro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4812958     DOI： 10.1001/archneur.1974.00490330030005

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  6 in total

1.  CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.

Authors:  J Dawn Waters; Carlos Sanchez; Ayguen Sahin; Diahnn Futalan; David D Gonda; Justin K Scheer; Johnny Akers; Kamalakannan Palanichamy; Peter Waterman; Arnab Chakravarti; Ralph Weissleder; Brent Morse; Nick Marsh; Eric Furfine; Clark C Chen; Irvith Carvajal; Bob S Carter
Journal:  J Neurooncol       Date:  2012-08-09       Impact factor: 4.130

2.  Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.

Authors:  S Genka; J Deutsch; P L Stahle; U H Shetty; V John; C Robinson; S I Rapoport; N H Greig
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Determination of subcutaneous tumor size in athymic (nude) mice.

Authors:  M M Tomayko; C P Reynolds
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  The additive effect of alpha-difluoromethylornithine (DFMO) and radiation therapy on a rat glioma model.

Authors:  T Tsukahara; M Tamura; H Yamazaki; H Kurihara; S Matsuzaki
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

6.  Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol.

Authors:  D J Stewart; M T Richard; H Hugenholtz; J Dennery; D Nundy; J Prior; V Montpetit; H S Hopkins
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.